Cardiac Problems Linked to Zelnorm
Last Updated on June 26, 2017
Investigation Complete
Attorneys working with ClassAction.org have finished their investigation into this matter. Check back for any potential updates. You can also sign up for our free newsletter for the latest in class action news and settlements.
If you still have questions about your rights, contact an attorney in your area as there is a time limit for filing all lawsuits. The information on this page was posted when the investigation began and is now for reference only.
Free Consumer Tools:
- Open and Current Class Action Lawsuit Settlements and Rebates
- Open and Current Class Action Lawsuit List, Investigations
- Class Action Lawsuit and Settlement News
- Free Class Action Lawsuit Database
At A Glance
- This Alert Affects
- If you have suffered a heart attack, stroke or chest pain while taking Zelnorm to treat constipation, you may be eligible to participate in Zelnorm litigation. A lawyer will be able to advise you of your legal rights and options.
- Damages
- Zelnorm has been linked with an increased chance of stroke, heart attack, and chest pain for some patients. Additional Zelnorm side effects include bowel, bladder or blood vessel perforation, vaginal scarring, recurrence of incontinence, urinary problems, infection, erosion through vaginal epithelium, recurrence of prolapse, dyspareunia, and pain.
- Company(ies)
- Novartis AG
- Additional Details
- Zelnorm (tegaserod maleate) is a prescription drug that helps treat constipation for individuals suffering from irritable bowel syndrome (IBS). It is intended for short term use in people under the age of 65.
- Date
- Zelnorm was recalled in March 2007 by Novartis.
Marketed by Novartis AG, Zelnorm is prescribed to help treat constipation in those suffering from irritable bowel syndrome, which is a functional bowel disorder. Zelnorm causes nerve cells to quicken the release of stools. Unfortunately, Zelnorm was taken off the market after it was associated with a number of cardiac problems.
In 2007, researched showed a link between Zelnorm and heart complications including angina, strokes and heart attacks. After influence from the FDA, Novartis took Zelnorm off the market in March 2007. Then, only a few months later, the FDA let Novartis market Zelnorm as an investigational drug, only to be given to people meeting specific criteria.
Before commenting, please review our comment policy.